ICD-10 Code C37: Malignant neoplasm of thymus

Key Takeaways

ICD-10 Code C37 is the billable diagnosis code for malignant neoplasm of thymus, valid for the 2026 coding year.

C37 covers thymoma and thymic carcinoma. Its ICD-10-CM Type 1 Excludes note applies to malignant carcinoid tumor of the thymus (C7A.091), which is coded separately.

Histological confirmation from pathology is required before submitting C37; coding without it can trigger claim denials under Medicare and commercial payers.

Pabau’s claims management software helps oncology and thoracic surgery practices submit C37 claims accurately and track denial patterns across payers.

Thymus malignancies are rare, but coding errors on these claims are common. ICD-10 Code C37 is the single billable code covering malignant neoplasm of thymus, yet its Type 1 Excludes note for thymic carcinoid tumors (C7A.091) and the clinical distinction from mediastinal cancers trip up even experienced coders. Getting it wrong means delayed reimbursement, payer audits, and potential compliance exposure for the practice.

This reference covers the clinical description of C37, its synonyms, excludes notes, related codes, documentation requirements, and billing considerations for healthcare providers and oncology and dermatology practices working with thymic malignancies.

ICD-10 Code C37: Definition and clinical description

Code: C37
Full description: Malignant neoplasm of thymus
Code system: ICD-10-CM (International Classification of Diseases, 10th Revision, Clinical Modification)
Chapter: C00-D49 (Neoplasms)
Section: C30-C39 (Malignant neoplasms of respiratory and intrathoracic organs)
Billable: Yes
Valid for: 2026 ICD-10-CM coding year

The thymus is a lymphoid organ located in the anterior mediastinum, behind the sternum. It plays a central role in immune system development, primarily during childhood, and involutes progressively after puberty. Malignant neoplasms of the thymus are rare, accounting for fewer than 1% of all thoracic malignancies. According to the Centers for Medicare and Medicaid Services (CMS), ICD-10-CM Code C37 is classified under malignant neoplasms of respiratory and intrathoracic organs and is valid for use in all HIPAA-covered transactions.

C37 captures all histological subtypes of thymic malignancy under a single code. There are no subcategory codes beneath C37 in ICD-10-CM – the code itself is the most granular classification available.

Synonyms and clinical terms mapped to C37

Several clinical terms index to C37 in the ICD-10-CM alphabetic index. Coders should recognize all of the following as valid synonyms when reviewing physician documentation.

• Malignant thymoma – the most common primary tumor of the anterior mediastinum in adults; a thymoma is considered malignant when it invades surrounding structures or metastasizes
• Malignant tumor of thymus – general term used in operative and pathology reports
• Neuroendocrine carcinoma of thymus – a distinct high-grade histological subtype arising from neuroendocrine cells within the thymus; note that well-differentiated thymic carcinoid (neuroendocrine) tumors are coded separately to C7A.091, not C37
• Thymic carcinoma – a high-grade malignancy with cytological atypia, distinct from thymoma in behavior and prognosis
• Thymus cancer – lay terminology that maps to C37 in clinical documentation

When a pathology report uses any of these terms, C37 is the correct principal diagnosis code. Coders should not attempt to assign a more specific code unless additional ICD-10-CM specificity exists, which it does not for thymic malignancies under the current classification system. The CDC/NCHS ICD-10-CM official tool confirms C37 as the sole billable code in this category.

Type 1 Excludes note and coding clarifications for C37

C37 carries one official ICD-10-CM Type 1 Excludes note: malignant carcinoid tumor of the thymus (C7A.091). A Type 1 Excludes note means the two codes are never used together – when a thymic tumor is a well-differentiated carcinoid (neuroendocrine) tumor, assign C7A.091 instead of C37. A separate but equally consequential rule is clinical rather than a coded excludes note: a malignancy is coded to C37 only when its origin is confirmed as the thymus, not the surrounding mediastinum.

Beyond that formal excludes note, a clinical site-of-origin distinction matters – although this one is coding guidance, not a coded ICD-10-CM excludes note. The thymus occupies the anterior mediastinum, but a malignancy is coded to C37 only when the origin is confirmed as the thymus gland itself. If imaging or pathology identifies the tumor as a primary mediastinal mass without confirmed thymic origin, the correct code is C38.1, C38.2, or C38.3 depending on location. Conflating these codes is one of the most common audit findings in thoracic oncology billing.

Coders should also be aware that ICD-O (International Classification of Diseases for Oncology) morphology codes are used in cancer registries and are distinct from ICD-10-CM. Do not substitute ICD-O codes in clinical billing records.

Related ICD-10 codes and crosswalks

C37 sits within a broader code hierarchy that coders and billers need to understand for accurate crosswalk and sequencing decisions. Below are the most relevant adjacent codes.

• C38.0 – Malignant neoplasm of heart
• C7A.091 – Malignant carcinoid tumor of the thymus (Type 1 Excludes from C37; used instead of C37 for thymic carcinoid tumors)
• C38.1 – Malignant neoplasm of anterior mediastinum (use when the origin is mediastinal, not thymic)
• C38.2 – Malignant neoplasm of posterior mediastinum (use when the origin is mediastinal, not thymic)
• C38.3 – Malignant neoplasm of mediastinum, part unspecified (use when the origin is mediastinal, not thymic)
• C38.4 – Malignant neoplasm of pleura
• C77.1 – Secondary and unspecified malignant neoplasm of intrathoracic lymph nodes (used for nodal spread)
• C78.1 – Secondary malignant neoplasm of mediastinum (metastatic disease)
• C79.89 – Secondary malignant neoplasm of other specified sites (for distant metastases)
• Z85.238 – Personal history of other malignant neoplasm of thymus (history coding after remission)

For practices tracking a range of complex ICD-10 diagnosis codes across their patient population, it is worth noting that C37 does not have laterality – the thymus is a midline structure, so no left/right distinction applies. This is different from many other neoplasm codes in the C30-C39 range. The WHO ICD-10 browser provides the international classification context for C37 within the broader neoplasm chapter.

Documentation requirements for C37

Accurate C37 documentation goes beyond writing “thymoma” in the assessment. Payers increasingly require specific supporting elements before approving claims for thymic malignancy.

Required elements in the medical record

• Histological confirmation: A pathology report identifying the tissue as malignant thymic tissue is the minimum requirement. A clinical impression alone, even supported by CT imaging, is insufficient for C37 assignment under most payer guidelines.
• Site of origin statement: The attending or treating physician must document that the malignancy arises from the thymus gland, not simply from the anterior mediastinum. This sentence directly determines whether C37 or C38.1 is correct.
• Tumor extent and invasion status: While ICD-10-CM does not require staging, operative and oncology notes should document whether the tumor invades adjacent structures. This affects clinical staging (Masaoka-Koga system) and supports medical necessity for surgical or multimodal treatment.
• Histological subtype if documented: Thymoma subtypes (WHO Types A, AB, B1, B2, B3) and thymic carcinoma are all coded to C37. However, the subtype should be documented in the record for clinical accuracy and registry reporting, even though ICD-10-CM does not differentiate them.
• Treatment intent: Whether the plan is curative, palliative, or adjuvant affects how secondary codes (e.g. Z51.11 for chemotherapy encounters) are sequenced alongside C37.

Well-structured medical documentation forms that prompt physicians for site of origin and histological subtype at the point of care reduce the downstream burden on coders. Practices using clinical records management tools can embed structured templates that capture these fields before the claim is generated, rather than chasing documentation after the fact.

For thoracic surgery encounters, the operative note must specify the procedure performed on the thymus (thymectomy, biopsy, or debulking) and confirm the intraoperative findings. This note, combined with the pathology report, forms the documentation backbone for C37 claims. Maintaining strong HIPAA compliance requirements around record retention and access is equally important for audit readiness.

Billing and reimbursement considerations

Thymic malignancy claims are low-volume but high-scrutiny. Several billing factors distinguish C37 from more routine oncology coding.

Prior authorization and payer requirements

Most commercial payers require prior authorization for thymectomy, chemotherapy, and radiation therapy associated with C37. The authorization request must include the histological confirmation, the staging documentation, and the proposed treatment plan. Submitting a prior authorization without pathology support is a common reason for initial denial.

Medicare covers thymectomy under its surgical benefit when medical necessity is established. Local Coverage Determinations (LCDs) vary by Medicare Administrative Contractor (MAC) jurisdiction, so practices should verify coverage specifics with their MAC before submitting. Using claims management software with payer-rule logic can flag missing authorization requirements before submission rather than after denial.

Sequencing C37 with secondary codes

C37 is typically sequenced as the principal diagnosis for inpatient thymic surgery admissions and as the first-listed diagnosis for outpatient oncology encounters. Secondary codes add clinical detail and support medical necessity.

• Z51.11 (Encounter for antineoplastic chemotherapy) – sequences after C37 when the visit purpose is chemotherapy administration
• Z51.0 (Encounter for antineoplastic radiation therapy) – sequences after C37 for radiation encounters
• G70.01 (Myasthenia gravis with acute exacerbation) – relevant when thymoma is associated with myasthenia gravis, a common paraneoplastic association; both conditions may be coded simultaneously
• C77.1 (Secondary malignant neoplasm of intrathoracic lymph nodes) – add when lymph node involvement is documented

The association between thymoma and myasthenia gravis deserves specific attention. Thymoma is present in approximately 15% of myasthenia gravis cases, and myasthenia gravis occurs in roughly 30-50% of thymoma patients. When both conditions are documented and treated in the same encounter, code both C37 and the appropriate G70 code. Payers accept dual coding here – do not omit the neurological condition.

Practices managing complex oncology billing across ICD-10-CM diagnosis coding for multiple specialties benefit from structured workflows that enforce sequencing rules at the point of charge capture. Strong compliance management processes reduce audit exposure when payers request supporting records for these claims.

For practices concerned about patient data security in oncology records, encrypted documentation and access controls are particularly important given the sensitivity of cancer diagnoses.

Common denial patterns

• Submitting C37 without a supporting pathology report on file
• Using C37 when documentation only supports an anterior mediastinal mass (correct code: C38.1)
• Missing prior authorization for thymectomy or multimodal oncology treatment
• Failing to code the associated myasthenia gravis (G70.01) when documented and treated
• Billing the wrong CPT code for thymectomy approach (thoracoscopic versus open requires different CPT selection)

Reduce C37 claim denials with Pabau

Pabau's claims management software helps oncology and thoracic surgery practices submit accurate ICD-10 claims, track denial patterns, and maintain audit-ready documentation across every payer.

Book a demo

Coding guidelines and clinical staging context

ICD-10-CM does not incorporate clinical staging into the C37 code structure. The code applies regardless of whether the thymoma is encapsulated or invasive, early-stage or metastatic. Staging is captured through documentation in the record and in cancer registry data using ICD-O and the Masaoka-Koga classification, but it does not change the ICD-10-CM code assignment.

The Masaoka-Koga system stages thymoma from Stage I (encapsulated, no capsular invasion) through Stage IV (pleural or pericardial dissemination, or hematogenous metastasis). For billing purposes, all stages code to C37. For medical necessity arguments with payers, however, staging documentation in the clinical notes significantly strengthens the authorization request for surgical resection or multimodal treatment.

The AAPC Codify ICD-10-CM resource confirms that C37 carries no laterality designator and no severity qualifier in the current code set. Any specificity beyond “malignant neoplasm of thymus” must be documented in the clinical record rather than reflected in a more granular ICD-10-CM code, because no such code exists. Practices building ICD-10-CM coding reference workflows across specialties should note this distinction.

WHO classification of thymic tumors and ICD-10 context

The WHO Classification of Tumors of the Thymus recognizes thymoma subtypes (Types A, AB, B1, B2, B3), thymic carcinoma, and thymic neuroendocrine tumors as distinct entities. Thymoma and thymic carcinoma map to C37 in ICD-10-CM, while well-differentiated thymic neuroendocrine (carcinoid) tumors are coded to C7A.091 under C37’s Type 1 Excludes note. Coders sometimes encounter confusion when a pathology report provides a WHO subtype designation – this is correct clinical specificity but does not change the ICD-10-CM code.

Thymic carcinoma (WHO Type C, now reclassified simply as thymic carcinoma) is biologically more aggressive than thymoma but is coded identically to C37. When a pathology report specifies thymic carcinoma versus thymoma, the distinction is clinically meaningful for treatment planning and prognosis but carries no ICD-10-CM coding difference.

Conclusion

ICD-10 Code C37 is straightforward in one sense – it is the only billable code for malignant neoplasm of thymus. The complexity lies in the documentation requirements, the Type 1 Excludes note for thymic carcinoid tumors (C7A.091), the clinical boundary with mediastinal codes, and the payer-specific prior authorization demands that accompany these rare but high-cost cases.

Pabau’s claims management software gives oncology and thoracic surgery practices the tools to capture structured documentation, enforce sequencing rules at charge entry, and track denial patterns before they compound into revenue cycle problems. To see how Pabau supports accurate ICD-10 coding workflows, book a demo with the team.

Continue your research

Need a structured approach to clinical documentation? Safer clinical notes covers documentation practices that reduce audit risk across oncology and specialist practices.

Managing compliance across a multi-provider practice? Medical spa compliance checklist outlines the documentation and regulatory controls relevant to clinical practices of all types.

Looking for ICD-10-CM coding guidance across specialties? Intraparenchymal hemorrhage ICD-10 codes shows how complex intracranial codes are structured and documented for billing.

Frequently Asked Questions